Clinical trials: Low and Intermediate Risk Prostate Cancer
Prostate Cancer
Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy
Optimal non surgical treatment of prostate cancer requires dose escalation which is frequently provided by adding a brachytherapy "boost" to a short course of external beam radiotherapy.
- Trial name
- BrachyQOL (NCT01936883)
- Testing
- HDR, LDR
- Where
- Canada
- Volunteers
- 195 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Transperineal Laser Ablation for Low- and Intermediate Risk Prostate Cancer: a Single Cohort Analysis
The goal of this prospective study is to test the efficacy of Echolaser transperineal focal therapy in patients with low- and intermediate risk prostate cancer. The main question it aims to answer are: 1.
- Trial name
- NCT05584787
- Testing
- Soractelite Echolaser Transperineal focal laser ablation
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- San Carlo di Nancy Hospital
Prostate Cancer, Cancer of the Prostate
A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors
The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients with early stage prostate cancer. The investigators hypothesize that hypofractionated stereotactic radiotherapy via the CyberKnife® can…
- Conditions
- Prostate Cancer, Cancer of the Prostate, Prostate Neoplasm
- Trial name
- NCT02225262
- Testing
- CyberKnife Radiosurgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Community Cancer Center, Normal, Illinois
Prostate Cancer
Intensity Modulated Versus Interstitial - Radiation Therapy
Purpose: The purpose of this trial is to compare two different treatment options for patients with low risk and low-tier intermediate risk prostate cancer.
- Trial name
- NCT00407875
- Testing
- Intensity Modulated External Beam Radiation Therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer
The primary objective of this study is to evaluate the safety and effectiveness of PFA in patients with localized prostate cancer.
- Trial name
- NCT07492381
- Testing
- ALPFA BPH PFA System
- Volunteers
- 50 people
- Sponsor
- ALPFA Medical
Prostate Cancer
Proton Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT01045226
- Testing
- Proton Beam Radiation Therapy, Quality-of-Life assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer
High-dose rate brachytherapy (HDR-BT) is an advanced technology theorized to be more advantageous than LDR-BT and External Beam Radiotherapy (EBRT), to the patient himself, and in terms of resource allocation.
- Trial name
- SINFRA_PROST (NCT02342054)
- Testing
- MRI-TRUS fusion guided Single Frac HDR
- Where
- Spain
- Volunteers
- 49 people
- Sponsor
- Hospital de Cruces
Prostate Cancer
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells.
- Trial name
- NCT06347705
- Testing
- 2141-V11 Antibody
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Hyaluronic Acid for Hypofractionated Prostate Radiotherapy
The present Phase II study aims to assess the rates of late rectal toxicities of grade ≥ 2 after hypofractionated radiotherapy of prostate cancer of 62 Gy in 20 fractions of 3.1 Gy with an injection of hyaluronic acid (HA) in the…
- Trial name
- RPAH1 (NCT02165020)
- Testing
- Hyaluronic acid (Macrolane VRF 30®, Q-MED)
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer
The main purpose of study is to evaluate hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients with low and intermediate risk of progression prostate cancer.
- Trial name
- CYBERPROST (NCT03225235)
- Testing
- SBRT
- Where
- Poland
- Volunteers
- 600 people
- Sponsor
- The Greater Poland Cancer Centre
Prostate Cancer
Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
This study will offer men with intermediate risk prostate cancer who are suitable for, and interested in, prostate brachytherapy, the opportunity to be randomized between low dose rate (LDR) brachytherapy using permanent…
- Trial name
- NCT02692105
- Testing
- Low dose rate prostate brachytherapy, High Dose Rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Quality of Life
Functional Outcomes and QoL in Patients With High Versus Low and Intermediate Risk Prostate Cancer Treated by RARP
The Be-RALP database is Belgian prospective multicenter database governed by the Belgian cancer registry. This database investigates the status after robot assisted laparoscopic prostatectomy (RALP) in prostate cancer patients.
- Conditions
- Prostate Cancer, Quality of Life, Erectile Function, Urinary Function
- Trial name
- NCT03790995
- Testing
- Robot assisted laparoscopic prostatectomy
- Where
- 25 sites in Belgium
- Volunteers
- 9,235 people
- Sponsor
- KU Leuven
Prostate Cancer
Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer
The purpose of this study is to determine the clinical efficacy and toxicity of High-dose rate (HDR) brachytherapy as monotherapy for the treatment of low risk and intermediate risk prostate cancer.
- Trial name
- NCT02077335
- Testing
- HDR brachytherapy monotherapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- CSSS de Gatineau
Prostate Cancer
LDR vs. HDR Brachytherapy for Prostate Cancer
H17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy.
- Trial name
- LDR/HDRmono (NCT03426748)
- Testing
- Low dose rate prostate brachytherapy, High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- British Columbia Cancer Agency
Prostatectomy
A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.
Prostate cancer (PCa) management for low- and intermediate-risk patients often involves radical prostatectomy (RP), which achieves oncologic control but is associated with significant functional impairments, such as erectile…
- Trial name
- NCT07348367
- Testing
- Radical Prostatectomy, Precision Prostatectomy
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Henry Ford Health System
Prostate Cancer
Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy
The TEMPOS-GEniToUrinary Group (GETUG) study is a multicenter, medico-economic study comparing brachytherapy to SBRT in low and intermediate risk prostate cancer, particularly focused on the issue of erectile dysfunction.
- Trial name
- TEMPOS (NCT03830788)
- Testing
- Radiation by brachytherapy, Radiation by SBRT
- Where
- 20 sites in France
- Volunteers
- 240 people
- Sponsor
- Center Eugene Marquis
Prostate Cancer
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to…
- Trial name
- HypoPro (NCT06772441)
- Testing
- Androgen deprivation therapy (ADT)
- Where
- Cyprus
- Volunteers
- 30 people
- Sponsor
- German Oncology Center, Cyprus
Prostate Cancer
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
The purpose of this study is to find out whether combining a shorter than standard course of ADT with standard prostate brachytherapy and hypofractionated external beam radiation therapy is a safe and effective way to prevent…
- Trial name
- NCT05100472
- Testing
- Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Validation Study on the Impact of Decipher® Testing - VANDAAM Study
The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same accuracy in African-American men (AAM) as…
- Trial name
- VANDAAM (NCT02723734)
- Testing
- Decipher® Testing
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Vaccination in Prostate Cancer (VANCE)
This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer.
- Trial name
- NCT02390063
- Testing
- ChAdOx1.5T4, MVA.5T4, Cyclophosphamide
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Oxford